Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients?

Bibliography

• Duchenne. The pathology of paralysis with muscular degeneration (paralysie myosclerotique), or paralysis with apparent hypertrophy. Br Med J 1867;2(363):541-2
   PubMedGoogle Scholar
• Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987;51(6):919-28
   PubMed Web of Science ®Google Scholar
• Drachman DB, Toyka KV, Myer E. Prednisone in Duchenne muscular dystrophy. Lancet 1974;2(7894):1409-12
   PubMed Web of Science ®Google Scholar
• Partridge TA, Morgan JE, Coulton GR, Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. Nature 1989;337(6203):176-9
   PubMed Web of Science ®Google Scholar
• Acsadi G, Dickson G, Love DR, Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs. Nature 1991;352(6338):815-18
   PubMed Web of Science ®Google Scholar
• Bogdanovich S, Krag TO, Barton ER, Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002;420(6914):418-21
   PubMed Web of Science ®Google Scholar
• Clemens PR, Duncan FJ. Progress in gene therapy for Duchenne muscular dystrophy. Curr Neurol Neurosci Rep 2001;1(1):89-96
   PubMedGoogle Scholar
• Tremblay JP, Malouin F, Roy R, Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy. Cell Transplant 1993;2(2):99-112
   PubMed Web of Science ®Google Scholar
• Wang Z, Storb R, Lee D, Immune responses to AAV in canine muscle monitored by cellular assays and noninvasive imaging. Mol Ther 2010;18(3):617-24
   PubMed Web of Science ®Google Scholar
• Chamberlain JS, Gregorevic P, Schultz B, Development of gene therapy for Duchenne muscular dystrophy using systemic delivery of AAV vectors. J Neurol Sci 2009;285:S124-4
   Web of Science ®Google Scholar
• Hoffman EP, Bronson A, Levin AA, Restoring dystrophin expression in Duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through. Am J Pathol 2011;179(1):12-22
   PubMed Web of Science ®Google Scholar
• Pramono ZA, Takeshima Y, Alimsardjono H, Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence. Biochem Biophys Res Commun 1996;226(2):445-9
   PubMed Web of Science ®Google Scholar
• Takeshima Y, Yagi M, Wada H, Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy. Pediatr Res 2006;59(5):690-4
   PubMed Web of Science ®Google Scholar
• Yokota T, Pistilli E, Duddy W, Nagaraju K. Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy. Expert Opin Biol Ther 2007;7(6):831-42
   PubMed Web of Science ®Google Scholar
• Malhotra SB, Hart KA, Klamut HJ, Frame-shift deletions in patients with Duchenne and Becker muscular dystrophy. Science 1988;242(4879):755-9
   PubMed Web of Science ®Google Scholar
• Yokota T, Duddy W, Partridge T. Optimizing exon skipping therapies for DMD. Acta Myol 2007;26(3):179-84
   PubMedGoogle Scholar
• Yokota T, Lu QL, Partridge T, Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 2009;65(6):667-76
   PubMed Web of Science ®Google Scholar
• Lu QL, Rabinowitz A, Chen YC, Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 2005;102(1):198-203
   PubMed Web of Science ®Google Scholar
• Aoki Y, Nakamura A, Yokota T, In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol Ther 2010;18(11):1995-2005
   PubMed Web of Science ®Google Scholar
• Cirak S, Arechavala-Gomeza V, Guglieri M, Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 2011;378(9791):595-605
   PubMed Web of Science ®Google Scholar
• Kinali M, Arechavala-Gomeza V, Feng L, Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 2009;8(10):918-28
   PubMed Web of Science ®Google Scholar
• Hammond SM, Wood MJ. PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy. Curr Opin Mol Ther 2010;12(4):478-86
   PubMed Web of Science ®Google Scholar
• van Deutekom JC, Janson AA, Ginjaar IB, Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007;357(26):2677-86
   PubMed Web of Science ®Google Scholar
• Goemans NM, Tulinius M, van den Akker JT, Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011;364(16):1513-22
   PubMed Web of Science ®Google Scholar
• Lu QL MC, Lou F, Bou-Gharios G, Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 2003;9(8):1009-14
   PubMed Web of Science ®Google Scholar
• Alter J, Lou F, Rabinowitz A, Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 2006;12(2):175-7
   PubMed Web of Science ®Google Scholar
• Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 1997;7(3):187-95
   PubMedGoogle Scholar
• Jearawiriyapaisarn N, Moulton HM, Buckley B, Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 2008;16(9):1624-9
   PubMed Web of Science ®Google Scholar
• Wu B, Moulton HM, Iversen PL, Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci USA 2008;105(39):14814-19
   PubMed Web of Science ®Google Scholar
• Morcos PA, Li Y, Jiang S. Vivo-Morpholinos: a non-peptide transporter delivers Morpholinos into a wide array of mouse tissues. Biotechniques 2008;45(6):613-14; 6, 8 passim
   PubMed Web of Science ®Google Scholar
• Wu B, Li Y, Morcos PA, Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Mol Ther 2009;17(5):864-71
   PubMed Web of Science ®Google Scholar
• Sheehan JP, Phan TM. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex by an allosteric mechanism. Biochemistry 2001;40(16):4980-9
   PubMed Web of Science ®Google Scholar
• Sheehan JP, Lan HC. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. Blood 1998;92(5):1617-25
   PubMed Web of Science ®Google Scholar
• Henry SP, Giclas PC, Leeds J, Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J Pharmacol Exp Ther 1997;281(2):810-16
   PubMed Web of Science ®Google Scholar
• Kurreck J. The role of backbone modifications in oligonucleotide-based strategies. In: Kurreck J, editor. Therapeutic oligonucleotides. The Royal Society of Chemistry; Cambridge, UK; 2008. p. 1-18
   Google Scholar
• Nishida A, Kataoka N, Takeshima Y, Chemical treatment enhances skipping of a mutated exon in the dystrophin gene. Nat Commun 2011;2:308
   PubMed Web of Science ®Google Scholar
• Dunckley MG, Manoharan M, Villiet P, Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet 1998;7(7):1083-90
   PubMed Web of Science ®Google Scholar
• Wilton SD, Lloyd F, Carville K, Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul Disord 1999;9(5):330-8
   PubMed Web of Science ®Google Scholar
• Mitrpant C, Fletcher S, Iversen PL, Wilton SD. By-passing the nonsense mutation in the 4 CV mouse model of muscular dystrophy by induced exon skipping. J Gene Med 2009;11(1):46-56
   PubMed Web of Science ®Google Scholar
• Aartsma-Rus A, Janson AA, Kaman WE, Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet 2004;74(1):83-92
   PubMed Web of Science ®Google Scholar
• Aartsma-Rus A, Janson AA, Kaman WE, Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet 2003;12(8):907-14
   PubMed Web of Science ®Google Scholar
• Takeshima Y, Yagi M, Okizuka Y, Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center. J Hum Genet 2010;55(6):379-88
   PubMed Web of Science ®Google Scholar
• Tuffery S, Chambert S, Bareil C, Mutation analysis of the dystrophin gene in Southern French DMD or BMD families: from Southern blot to protein truncation test. Hum Genet 1998;102(3):334-42
   PubMed Web of Science ®Google Scholar
• Helderman-van den Enden AT, Straathof CS, Aartsma-Rus A, Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients. Neuromuscul Disord 2010;20(4):251-4
   PubMed Web of Science ®Google Scholar
• van Vliet L, de Winter CL, van Deutekom JC, Assessment of the feasibility of exon 45-55 multiexon skipping for Duchenne muscular dystrophy. BMC Med Genet 2008;9:105
   PubMed Web of Science ®Google Scholar
• Yokota T, Takeda S, Lu QL, A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground. Arch Neurol 2009;66(1):32-8
   PubMed Web of Science ®Google Scholar
• Beroud C, Tuffery-Giraud S, Matsuo M, Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum Mutat 2007;28(2):196-202
   PubMed Web of Science ®Google Scholar
• Aartsma-Rus A, Fokkema I, Verschuuren J, Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 2009;30(3):293-9
   PubMed Web of Science ®Google Scholar
• Aartsma-Rus A, Van Deutekom JC, Fokkema IF, Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 2006;34(2):135-44
   PubMed Web of Science ®Google Scholar
• Cirak S, Feng L, Anthony K, Restoration of the Dystrophin-associated glycoprotein complex after exon skipping therapy in duchenne muscular dystrophy. Mol Ther 2012;20(2):462-7
   PubMed Web of Science ®Google Scholar
• Wapenaar MC, Kievits T, Hart KA, A deletion hot spot in the Duchenne muscular dystrophy gene. Genomics 1988;2(2):101-8
   PubMedGoogle Scholar
• Sironi M, Pozzoli U, Comi GP, A region in the dystrophin gene major hot spot harbors a cluster of deletion breakpoints and generates double-strand breaks in yeast. FASEB J 2006;20(11):1910-12
   PubMed Web of Science ®Google Scholar
• Blonden LA, Grootscholten PM, den Dunnen JT, 242 breakpoints in the 200-kb deletion-prone P20 region of the DMD gene are widely spread. Genomics 1991;10(3):631-9
   PubMed Web of Science ®Google Scholar
• Gurvich OL, Tuohy TM, Howard MT, DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy. Ann Neurol 2008;63(1):81-9
   PubMed Web of Science ®Google Scholar
• Flanigan KM, Dunn DM, von Niederhausern A, DMD Trp3X nonsense mutation associated with a founder effect in North American families with mild Becker muscular dystrophy. Neuromuscul Disord 2009;19(11):743-8
   PubMed Web of Science ®Google Scholar
• Flanigan KM, Dunn DM, von Niederhausern A, Nonsense mutation-associated Becker muscular dystrophy: interplay between exon definition and splicing regulatory elements within the DMD gene. Hum Mutat 2011;32(3):299-308
   PubMed Web of Science ®Google Scholar
• Menhart N. Hybrid spectrin type repeats produced by exon-skipping in dystrophin. Biochim Biophys Acta 2006;1764(6):993-9
   PubMed Web of Science ®Google Scholar
• Ruszczak C, Mirza A, Menhart N. Differential stabilities of alternative exon-skipped rod motifs of dystrophin. Biochim Biophys Acta 2009;1794(6):921-8
   PubMed Web of Science ®Google Scholar
• Henderson DM, Belanto JJ, Li B, Internal deletion compromises the stability of dystrophin. Hum Mol Genet 2011;20(15):2955-63
   PubMed Web of Science ®Google Scholar
• Legrand B, Giudice E, Nicolas A, Computational study of the human dystrophin repeats: interaction properties and molecular dynamics. PLoS One 2011;6(8):e23819
   PubMedGoogle Scholar
• Klietsch R, Ervasti JM, Arnold W, Dystrophin-glycoprotein complex and laminin colocalize to the sarcolemma and transverse tubules of cardiac muscle. Circ Res 1993;72(2):349-60
   PubMed Web of Science ®Google Scholar
• Blake DJ, Nawrotzki R, Peters MF, Isoform diversity of dystrobrevin, the murine 87-kDa postsynaptic protein. J Biol Chem 1996;271(13):7802-10
   PubMed Web of Science ®Google Scholar
• Adams ME, Butler MH, Dwyer TM, Two forms of mouse syntrophin, a 58 kd dystrophin-associated protein, differ in primary structure and tissue distribution. Neuron 1993;11(3):531-40
   PubMed Web of Science ®Google Scholar
• Newbell BJ, Anderson JT, Jarrett HW. Ca2+-calmodulin binding to mouse alpha1 syntrophin: syntrophin is also a Ca2+-binding protein. Biochemistry 1997;36(6):1295-305
   PubMed Web of Science ®Google Scholar
• Chung W, Campanelli JT. WW and EF hand domains of dystrophin-family proteins mediate dystroglycan binding. Mol Cell Biol Res Commun 1999;2(3):162-71
   PubMedGoogle Scholar
• Hosaka Y, Yokota T, Miyagoe-Suzuki Y, Alpha1-syntrophin-deficient skeletal muscle exhibits hypertrophy and aberrant formation of neuromuscular junctions during regeneration. J Cell Biol 2002;158(6):1097-107
   PubMed Web of Science ®Google Scholar
• Kameya S, Miyagoe Y, Nonaka I, alpha1-syntrophin gene disruption results in the absence of neuronal-type nitric-oxide synthase at the sarcolemma but does not induce muscle degeneration. J Biol Chem 1999;274(4):2193-200
   PubMed Web of Science ®Google Scholar
• Yokota T, Hosaka Y, Tsukita K, Aquaporin-4 is absent at the sarcolemma and at perivascular astrocyte endfeet in alpha1-syntrophin knockout mice. Proc Japan Acad 2000;76B:22-7
   Google Scholar
• Adams ME, Mueller HA, Froehner SC. In vivo requirement of the alpha-syntrophin PDZ domain for the sarcolemmal localization of nNOS and aquaporin-4. J Cell Biol 2001;155(1):113-22
   PubMed Web of Science ®Google Scholar
• Munehira Y, Ohnishi T, Kawamoto S, Alpha1-syntrophin modulates turnover of ABCA1. J Biol Chem 2004;279(15):15091-5
   PubMed Web of Science ®Google Scholar
• Corrado K, Rafael JA, Mills PL, Transgenic mdx mice expressing dystrophin with a deletion in the actin-binding domain display a "mild Becker" phenotype. J Cell Biol 1996;134(4):873-84
   PubMed Web of Science ®Google Scholar
• Heald A, Anderson LV, Bushby KM, Shaw PJ. Becker muscular dystrophy with onset after 60 years. Neurology 1994;Dec44(12):2388-90
   PubMed Web of Science ®Google Scholar
• McClorey G, Moulton HM, Iversen PL, Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther 2006;13(19):1373-81
   PubMed Web of Science ®Google Scholar
• Saito T, Nakamura A, Aoki Y, Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient. PLoS One 2010;5(8):e12239
   PubMed Web of Science ®Google Scholar
• Bish LT, Sleeper MM, Forbes SC, Long-term restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skipping. Mol Ther 2012;20(3):580-9
   PubMed Web of Science ®Google Scholar
• Yokota T, Hoffman E, Takeda S. Antisense oligo-mediated multiple exon skipping in a dog model of Duchenne muscular dystrophy. Methods Mol Biol 2011;709:299-312
   PubMedGoogle Scholar
• Ginjaar IB, Kneppers AL, v d Meulen JD, Dystrophin nonsense mutation induces different levels of exon 29 skipping and leads to variable phenotypes within one BMD family. Eur J Hum Genet 2000;8(10):793-6
   PubMed Web of Science ®Google Scholar
• Hamed SA. Drug evaluation: PTC-124–a potential treatment of cystic fibrosis and Duchenne muscular dystrophy. IDrugs 2006;9(11):783-9
   PubMed Web of Science ®Google Scholar
• Barton-Davis ER, Cordier L, Shoturma DI, Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999;104(4):375-81
   PubMed Web of Science ®Google Scholar
• Arakawa M, Shiozuka M, Nakayama Y, Negamycin restores dystrophin expression in skeletal and cardiac muscles of mdx mice. J Biochem 2003;134(5):751-8
   PubMed Web of Science ®Google Scholar
• Aurino S, Nigro V. Readthrough strategies for stop codons in Duchenne muscular dystrophy. Acta Myol 2006;25(1):5-12
   PubMedGoogle Scholar
• Welch EM, Barton ER, Zhuo J, PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007;447(7140):87-91
   PubMed Web of Science ®Google Scholar
• Dunant P, Walter MC, Karpati G, Lochmuller H. Gentamicin fails to increase dystrophin expression in dystrophin-deficient muscle. Muscle Nerve 2003;27(5):624-7
   PubMed Web of Science ®Google Scholar
• Malik V, Rodino-Klapac LR, Viollet L, Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol 2010;67(6):771-80
   PubMed Web of Science ®Google Scholar
• Wilton S. PTC124, nonsense mutations and Duchenne muscular dystrophy. Neuromuscul Disord 2007;17(9-10):719-20
   PubMed Web of Science ®Google Scholar
• Wilschanski M, Miller LL, Shoseyov D, Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 2011;38(1):59-69
   PubMed Web of Science ®Google Scholar
• Pichavant C, Aartsma-Rus A, Clemens PR, Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol Ther 2011;19(5):830-40
   PubMed Web of Science ®Google Scholar
• Goyenvalle A, Babbs A, Powell D, Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping. Mol Ther 2010;18(1):198-205
   PubMed Web of Science ®Google Scholar
• Goyenvalle A, Babbs A, Wright J, Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping. Hum Mol Genet 2012; doi: 10.1093/hmg/dds082 First published online: March 2, 2012
   PubMed Web of Science ®Google Scholar
• Finsterer J, Stollberger C. The heart in human dystrophinopathies. Cardiology 2003;99(1):1-19
   PubMed Web of Science ®Google Scholar
• Porensky PN, Mitrpant C, McGovern VL, A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum Mol Genet 2012;21(7):1625-38
   PubMed Web of Science ®Google Scholar
• Hua Y, Sahashi K, Rigo F, Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011;478(7367):123-6
   PubMed Web of Science ®Google Scholar
• Barthelemy F, Wein N, Krahn M, Translational research and therapeutic perspectives in dysferlinopathies. Mol Med 2011;17(9-10):875-82
   PubMed Web of Science ®Google Scholar
• Aartsma-Rus A, Singh KH, Fokkema IF, Therapeutic exon skipping for dysferlinopathies? Eur J Hum Genet 2010;18(8):889-94
   PubMed Web of Science ®Google Scholar
• Wein N, Avril A, Bartoli M, Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping. Hum Mutat 2010;31(2):136-42
   PubMed Web of Science ®Google Scholar
• Hu J, Matsui M, Gagnon KT, Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol 2009;27(5):478-84
   PubMed Web of Science ®Google Scholar
• Meghan S, Neil A. RNA- and DNA- based therapies for Huntington's disease. In: Lo DC, Hughes RE, editors. Chapter 9. Frontiers in Neuroscience. . Neurobiology of Huntington's Disease: Applications to Drug Discovery. Boca Raton (FL): CRC Press;2011
   Google Scholar
• Taniguchi-Ikeda M, Kobayashi K, Kanagawa M, Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy. Nature 2011;478(7367):127-31
   PubMed Web of Science ®Google Scholar
• Galderisi U, Cipollaro M, Melone MA, Myotonic dystrophy: antisense oligonucleotide inhibition of DMPK gene expression in vitro. Biochem Biophys Res Commun 1996;221(3):750-4
   PubMed Web of Science ®Google Scholar
• Wheeler TM, Sobczak K, Lueck JD, Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 2009;325(5938):336-9
   PubMed Web of Science ®Google Scholar
• Wheeler TM, Lueck JD, Swanson MS, Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest 2007;117(12):3952-7
   PubMed Web of Science ®Google Scholar
• Lu QL, Yokota T, Takeda S, The status of exon skipping as a therapeutic approach to Duchenne muscular dystrophy. Mol Ther 2011;19(1):9-15
   PubMed Web of Science ®Google Scholar
• Wilton SD, Fall AM, Harding PL, Antisense Oligonucleotide-induced exon skipping across the human Dystrophin gene transcript. Mol Ther 2007;15(7):1288-96
   PubMed Web of Science ®Google Scholar
• Aartsma-Rus A, Janson AA, van Ommen GJ, van Deutekom JC. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy. BMC Med Genet 2007;8:43
   PubMed Web of Science ®Google Scholar